Clinical Trial Update: Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial of APG-115 (Alrizomadlin) for BAP1 tumor predisposition syndrome with mesothelioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bap1 Tumor Predisposition Syndrome
• Malignant Mesothelioma

Drugs mentioned

• APG-115 (APG-115)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Status: WITHDRAWN